Dr. S. Vincent Rajkumar on a New Bortezomib Triplet in Multiple Myeloma
S. Vincent Rajkumar, MD, discusses bortezomib, lenalidomide, and dexamethasone coming out on top in a recent phase III trial over lenalidomide and dexamethasone alone.
S. Vincent Rajkumar, MD, professor of medicine, Mayo Clinic, discusses bortezomib, lenalidomide, and dexamethasone coming out on top in a recent phase III trial over lenalidomide and dexamethasone alone.
The findings of the phase III trial, labeled SWOG S0777, showed a 13-month improvement in progression-free survival and a 29% reduction of risk of death with the triplet of bortezomib, lenalidomide, and dexamethasone, compared with lenalidomide and dexamethasone alone. Findings from the study suggest the triplet should be a new standard of care for untreated patients with multiple myeloma. Rajkumar said the triplet is now the new standard of care at the Mayo Clinic for multiple myeloma.
Real-World RRMM Data Explore Dose Deescalation and Outpatient Use of Teclistamab
November 18th 2024During a Case-Based Roundtable® event, Hana Safah, MD, examined several real-world studies of dose frequency and outpatient administration of teclistamab in patients with multiple myeloma in the first article of a 2-part series.
Read More
